Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/19 03:59:58 pm
53.3 EUR   +1.27%
01/18GLOBAL MARKETS LIVE: Deliveroo, Zurich Insurance, Bayer…
01/18BAYER AG : JP Morgan sticks Neutral
MD
01/17Bayer aims to help CureVac with COVID-19 vaccine output, says CEO
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : U.S. judge rejects $648 million Bayer PCB contamination settlement

11/30/2020 | 08:31pm EST
FILE PHOTO: The historic headquarters of German pharmaceutical and chemical maker Bayer AG is pictured in Leverkusen

(Reuters) - A federal judge has rejected Bayer AG's proposed $648 million settlement of class-action litigation by cities and other claimants over contamination from polychlorinated biphenyls, or PCBs, made by the former Monsanto Co.

In a Nov. 25 decision, U.S. District Judge Fernando Olguin in Los Angeles said the accord appeared "overly broad" because it could shield Bayer from future claims, and require the settling plaintiffs to indemnify Bayer against those claims.

Olguin also said most of the 2,528 class members stood to receive "very modest" payments of just $15,000 to $30,000, making the indemnification provision "troubling."

Bayer, which bought Monsanto for $63 billion in 2018, said in a statement it would work with the plaintiffs to address Olguin's concerns, and was confident it would reach a revised preliminary settlement by the Dec. 31 deadline he set.

Los Angeles County and the cities of San Diego, Baltimore and Portland, Oregon are among the plaintiffs, which came from 36 U.S. states. The payout was to include $550 million for class members and up to $98 million for legal fees and expenses.

The German company announced the settlement in June, when it also proposed paying roughly $12 billion to resolve litigation tied to Monsanto.

Most of that was to resolve claims that Monsanto's Roundup weedkiller caused cancer. Bayer has said Roundup is safe for human use.

PCBs were once used widely to insulate electrical equipment, and also used in such products as carbonless copy paper, caulking, floor finish and paint. They were outlawed by the U.S. government in 1979 after being linked to cancer and other health problems. Monsanto produced PCBs from 1935 to 1977.

The case is City of Long Beach et al v. Monsanto Co, U.S. District Court, Central District of California, No. 16-03493.

(Reporting by Jonathan Stempel in New York; Editing by Edwina Gibbs)

By Jonathan Stempel


© Reuters 2020
All news about BAYER AG
01/18GLOBAL MARKETS LIVE: Deliveroo, Zurich Insurance, Bayer…
01/18BAYER AG : JP Morgan sticks Neutral
MD
01/17Bayer aims to help CureVac with COVID-19 vaccine output, says CEO
RE
01/15Bans on GMO corn, glyphosate in Mexico would shrink food supplies, industry s..
RE
01/14BAYER AG : NorldLB reaffirms its Buy rating
MD
01/13GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
01/13LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
01/13BAYER : U.S. FDA grants Priority Review to New Drug Application for finerenone t..
AQ
01/13BAYER : J.P. Morgan Healthcare Conference, virtuell
PU
01/13BAYER : New Prostate Cancer Drug Exceeds Sales Forecasts
MT
More news
Financials
Sales 2020 42 032 M 51 035 M 51 035 M
Net income 2020 -10 175 M -12 355 M -12 355 M
Net Debt 2020 33 806 M 41 047 M 41 047 M
P/E ratio 2020 -4,33x
Yield 2020 4,17%
Capitalization 52 078 M 63 125 M 63 233 M
EV / Sales 2020 2,04x
EV / Sales 2021 2,03x
Nbr of Employees 100 618
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 61,56 €
Last Close Price 53,01 €
Spread / Highest target 60,3%
Spread / Average Target 16,1%
Spread / Lowest Target -13,2%
EPS Revisions
Managers and Directors
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG10.08%62 446
JOHNSON & JOHNSON3.43%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.22%203 993